Utrecht Spina Bifida And Graded Exercise (USAGE) Study part 2: Does training in ambulatory children with SB increase levels of physical fitness, energy cost of locomotion and daily physical activity?

Utrecht Spina Bifida And Graded Exercise (USAGE) Study part 2: Does training in ambulatory children with SB improve levels of physical fitness, energy cost of locomotion and daily physical activity?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27772

Enrollment

Registered

2008-11-20

Start date

2009-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spina Bifida Exercise training Physical fitness Energy cost of locomotion Physical activity level

Interventions

Supervised treadmill training, twice a week at home, for twelve weeks.

Eligibility

Inclusion criteria

Inclusion criteria: - Ambulatory children and adolescents with SB, type MMC or LMMC. Inclusion criteria: 1. At least community ambulatory (be able to ambulate >100 meters outside the home) 2. Be able to follow instructions regarding testing and training. 3. Parental and child informed consent. 4. Age 6-18 years of age.

Exclusion criteria

Exclusion criteria: 1. Insufficient understanding of the Dutch language in both children and parents. 2. Medical events that will not allow exercise testing and/or training. 3. Children participating in high level sports and/or more than 3 hours a week. 4. Severe cognitive impairments (IQ<80)

Design outcomes

Primary

Measure	Time frame
- Physical fitness (VO2peak and strength) - Energy cost of locomotion - Distance walked during six-minute walk test	—

Secondary

Measure	Time frame
- Physical activity level (PAL) - Daily fatigue (PedsQL)	—

Contacts

Public ContactJ.F. Groot, de

Wilhelmina Children's Hospital University medical center Utrecht PO 85090 Room KB.02.056.0

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)